Incyte (INCY) FY2025 10-K Annual Report
Incyte (INCY) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 10, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Incyte FY2025 10-K Analysis
Business Overview
- • Core business: Biopharmaceutical company focused on development, commercialization, and licensing of innovative drugs
- • New products emphasized: NIKTIMVO commercial launch in Q1 2025; ZYNYZ approved for squamous cell anal carcinoma in Q2 2025
Management Discussion & Analysis
- • Revenue $3.5B, up 8% YoY driven by JAKAFI and new product growth
- • Operating margin 22.4% vs 19.7% reflecting improved cost efficiencies
Risk Factors
- • Regulatory risk: ongoing contract dispute settlement expense of $242M recognized in fiscal 2025
- • Macroeconomic exposure: 93% of total revenues ($4.8B of $5.1B) from U.S. market concentration
Incyte FY2025 Key Financial MetricsXBRL
Revenue
$5.1B
▲ +21.2% YoY
Net Income
$1.3B
▲ +3845.0% YoY
Operating Margin
29.5%
▲ +2802bp YoY
Net Margin
25.0%
▲ +2426bp YoY
ROE
24.9%
▲ +2395bp YoY
Total Assets
$7.0B
▲ +27.8% YoY
EPS (Diluted)
$6.41
▲ +4173.3% YoY
Operating Cash Flow
$1.4B
▲ +321.5% YoY
Source: XBRL data from Incyte FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Incyte
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.